Form 4: Kiromic Biopharma Director Michael Nagel Acquires 1,000 Shares

Director Michael Nagel of Kiromic Biopharma, Inc. purchased 1,000 shares of common stock on June 11, 2024.

Summary

• On June 11, 2024, Michael Nagel, a director of Kiromic Biopharma, Inc., acquired 1,000 shares of common stock.
• The purchase price was $3.33 per share.
• Following the transaction, Nagel directly owns 43,296 shares of Kiromic Biopharma's common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It reflects a routine transaction by a company director. While insider buying can be seen as a positive signal, the purchase is relatively small and doesn't necessarily indicate a strong bullish outlook.

Positives

• A director's purchase of company stock can be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Form 4 filings are standard disclosures required by the SEC to provide transparency regarding the transactions of company insiders.

Stakeholder Impact

• The purchase could have a slightly positive impact on shareholders, as it may signal confidence from a company insider.

Key Dates

Keywords

Kiromic Biopharma, KRBP, Michael Nagel, Director, Stock Purchase, Form 4, Beneficial Ownership